Patents by Inventor Sander G. Mills

Sander G. Mills has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiro-substituted azacycles as modulators of chemokine receptor activity
    Patent number: 6013644
    Abstract: The present invention is directed spiro-substituted azacycles of formula I: (wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, k, l and m are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: January 11, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Sander G. Mills, Malcolm Maccoss, Martin S. Springer
  • Spiro-substituted azacycles as modulators of chemokine receptor activity
    Patent number: 5962462
    Abstract: The present invention is directed to spiro-substituted azacycles of the Formula 1: ##STR1## (wherein R.sub.1, l, m, Q, W, X, Y, and Z are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: October 5, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Sander G. Mills, Malcolm Maccoss, Martin S. Springer
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent number: 5922706
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: July 13, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Tamara Ladduwahetty
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent number: 5872116
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: February 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Spiro-substituted azacycles as tachykinin receptor antagonists
    Patent number: 5869496
    Abstract: Disclosed are spiro-substituted azacycles of formula (I), are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, emesis and asthma. In particular compounds of formula (I) are shown to be neurokinin antagonists.
    Type: Grant
    Filed: July 11, 1995
    Date of Patent: February 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Hongbo Qi, Shrenik K. Shah
  • Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
    Patent number: 5780467
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: July 14, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills
  • Cycloalkyl tachykinin receptor antagonists
    Patent number: 5750549
    Abstract: The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.
    Type: Grant
    Filed: October 15, 1996
    Date of Patent: May 12, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Charles G. Caldwell, Ping Chen, Philippe L. Durette, Paul Finke, Jeffrey Hale, Edward Holson, Ihor Kopka, Malcolm MacCoss, Laura Meurer, Sander G. Mills, Albert Robichaud
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent number: 5719147
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: February 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm MacCoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Treatment of migraine with morpholine tachykinin receptor antagonists
    Patent number: 5716942
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: February 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Malcolm MacCoss, Jeffrey J. Hale, Sander G. Mills
  • Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
    Patent number: 5691336
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills
  • Process for preparing morpholine tachykinin receptor antagonists
    Patent number: 5637699
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 10, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J. Hale, Paul E. Finke, Malcolm MacCoss, Sander G. Mills, Shrenik K. Shah, Mark S. Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian J. Williams
  • N-acylpiperidine tachykinin antagonists
    Patent number: 5610165
    Abstract: N-Acylpiperidines of general structure ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.
    Type: Grant
    Filed: February 17, 1994
    Date of Patent: March 11, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Malcolm MacCoss, Sander G. Mills
  • Substituted aryl piperazines as neurokinin antagonists
    Patent number: 5607936
    Abstract: Disclosed are substituted aryl piperazines of Formula I ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis. In particular compounds of Formula I are shown to be neurokinin antagonists.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: March 4, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Yuan-Ching P. Chiang, Paul E. Finke, Malcolm Maccoss, Laura C. Meurer, Daniel J. Miller, Sander G. Mills, Albert J. Robichaud, Shrenik K. Shah
  • Substituted azetidinones as anti-inflammatory and antidegenerative agents
    Patent number: 5591737
    Abstract: New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. ##STR1## wherein R.sub.4 is (a) ##STR2## or (b) ##STR3## where R.sub.x is carboxy C.sub.1-6 alkyl, benzyloxycarbonylC.sub.1-3 alkyl, or t-butoxycarbonylC.sub.1-3 alkyl,whereinQ is a covalent bond or ##STR4## wherein R.sub.5 and R.sub.6 are each individually C.sub.1-3 alkyl or hydrogen,Y is ##STR5## or a covalent bond.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: January 7, 1997
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Conrad P. Dorn, Philippe L. Durette, Paul E. Finke, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Soumya P. Sahoo, Jeffrey J. Hale, Thomas J. Lanza, William K. Hagmann
  • Treatment of emesis with morpholine tachykinin receptor antagonists
    Patent number: 5512570
    Abstract: Substituted heterocycles of the structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: April 30, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Malcolm MacCoss, Jeffrey J. Hale, Sander G. Mills
  • Process for synthesis of FK-506 and tricarbonyl intermediates
    Patent number: 5446158
    Abstract: A process is described for the total synthesis of the macrolide immunosuppressant, FK-506, and important tricarbonyl process intermediates thereof. The tricarbonyl intermediates can be produced by the mild oxidation of 2,3-dihydroxy carboxylate compounds containing olefin moieties.
    Type: Grant
    Filed: October 12, 1990
    Date of Patent: August 29, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Todd K. Jones, Sander G. Mills, David Askin, Robert A. Reamer, Richard Desmond, David M. Tschaen, Ralph P. Volante, Ichiro Shinkai
  • Process of making chiral 2-aryl-1,4-butanediamine derivatives as useful neurokinin-A antagonists
    Patent number: 5391819
    Abstract: Disclosed herein is a process of making chiral 2-aryl-1,4-butanediamine derivatives useful as neurokinin-A antagonists of Formula 7 ##STR1##
    Type: Grant
    Filed: September 30, 1992
    Date of Patent: February 21, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills
  • Alicyclic compounds as tachykinin receptor antagonists
    Patent number: 5387595
    Abstract: Substituted alicyclic compounds of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma.
    Type: Grant
    Filed: August 26, 1992
    Date of Patent: February 7, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Sander G. Mills, Paul E. Finke, Malcolm MacCoss, Daniel J. Miller, Dennis J. Underwood
  • N,N-diacylpiperazine tachykinin antagonists
    Patent number: 5344830
    Abstract: Diacylpiperazines of general structure ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: December 10, 1992
    Date of Patent: September 6, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Sander G. Mills, Richard J. Budhu, Conrad P. Dorn, William J. Greenlee, Malcolm MacCoss, Mu T. Wu
  • N,N-diacylpiperazines
    Patent number: 5292726
    Abstract: Diacylpiperazines of general structure ##STR1## are: angiotensin II (A-II) antagonists selective for the type 2 (AT.sub.2) subtype useful in the treatment of cerebrovascular, cognitive, and CNS disorders; tachykinin receptor antagonists useful in the treatment of inflammatory diseases and pain or migraine; and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: May 19, 1992
    Date of Patent: March 8, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Wallace T. Ashton, Conrad P. Dorn, William J. Greenlee, Malcolm MacCoss, Sander G. Mills, Mu T. Wu